Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. High Incidence of Thromboembolism in Patients With mRCC Treated With Immunotherapy
  2. First-Line Nivolumab + Ipilimumab in Patients Without Nephrectomy in the CheckMate 214 Trial
  3. Definitive Radiotherapy in Lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma
  4. Cabozantinib After Progression Improves Survival in Advanced Renal Cell Carcinoma
  5. Cabozantinib for Brain Metastases in Patients With RCC
  6. Evolving Biological Associations of Upfront Cytoreductive Nephrectomy in Metastatic RCC
  7. Blood Volume as a Functional Image-Based Biomarker of Progression in mRCC
  8. Nivolumab and Stereotactic Body Radiotherapy in Patients With Metastatic RCC
  9. The Significance of PARP1 as a Biomarker for Response to PD-L1 Blockade in Patients With PBRM1-Mutated ccRCC
  10. Low Post-Protocol Immunotherapy Use in Kidney Cancer RCTs

Elsewhere

Recently Updated